RACE ONCOLOGY - Key Persons

Job Titles:

• Chief Medical Officer
• Chairman - Clinical Advisory Board
• Professor, Department of Stem Cell Transplantation

Borje S. Andersson is Professor, Department of Stem Cell Transplantation in the Division of Cancer Medicine at University of Texas MD Anderson Cancer Center in Houston, Texas and Director of the Department's program for Molecular Pharmacology and Translational Drug Development. He is also Adjunct Professor, University of Houston College of Pharmacy in Houston. He received his medical degree from Karolinska Institute Faculty of Medicine and is board-certified in medical oncology, internal medicine and haematology. He has been an active researcher in the leukaemia field and his recent research has focused on the development of less toxic and more efficacious pre-transplant conditioning therapies, and improving the understanding of leukaemic cell resistance to bifunctional DNA-alkylating agents.

Job Titles:

• Chief Executive Officer
• Member of the Management Team
• Founder and CEO of Nucleics

Dr Daniel Tillett is the founder and CEO of Nucleics, a private Australian biotechnology company producing and selling world leading DNA sequencing software to the Genomics industry. Nucleics SAAS (software as a service) genomics tools are in use in more than 30 countries and at over 250 companies and institutions. Dr Tillett has extensive commercial experience over the last 20 years in the biotech industry in project management, sales and marketing, IP management, fundraising and start-up investing. Previously, he was a Senior Lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, microbiology, bioinformatics and cancer. Dr Tillett has a PhD from the University of New South Wales in Molecular Genetics and Biochemistry. He has more than 40 scientific publications and granted patents in molecular biology, microbiology, genetics and biochemistry.

Job Titles:

• Clinical Program Director
• Clinical Trials Specialist

Dr Marinella Messina is highly experienced oncology clinical trials specialist, having managed a wide range of clinical trials over the past 10 years, across all development phases (I, II, III and IV). Dr Messina has worked with bio pharmaceutical companies and academic research investigators during this time, including Noxopharm where she was Clinical Operations Manager and Clinical Program Manager for their lead anti-cancer drug candidate Veyonda®. Prior to this, Dr Messina was a Senior Clinical Project Manager at Datapharm, an Australian Clinical Research Organisation (CRO), where she oversaw the start-up, recruitment and management of numerous clinical trials. Dr Messina holds a Doctor of Philosophy from the Faculty of Medicine at the University of Sydney, and a Bachelor of Science (Honours) from the Department of Microbiology at the University of Sydney. She is also a Certified Medical Publication Professional and has been published extensively in a broad range of peer-reviewed publications.

Job Titles:

• Chief Medical Officer
• Member of the Management Team

Dr Michelle Rashford serves as Race Oncology's Chief Medical Officer (CMO), and is an internationally experienced biopharmaceutical executive and former physician, with expertise in the successful development and commercialisation of pharmaceuticals across oncology, virology, and immunology. Her 25+ years of drug development experience spans large pharmaceuticals to smaller biotech companies and includes pre-clinical and clinical development, medical and regulatory affairs, and drug commercialisation. Prior to joining Race, Dr Rashford worked for japanese Pharmaceutical company Kyowa Kirin, where she has been the Head of Global Clinical Sciences. Prior to her role at Kyowa Kirin, Dr Rashford was the Senior Vice President of Clinical Science at Adlai Nortye Biopharma, where she successfully grew the US Clinical Development team and prepared for the company's Phase III trial. She has also held senior roles within global pharmaceutical companies, including five years at Bristol-Myers Squibb and close to 20 years at Roche in a variety of national and global clinical development roles.

Job Titles:

• Executive Director
• Member of the Board of Directors

Dr Peter Smith has over 30 years of experience in the pharmaceutical and biotech industry, with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private biotechnology company Myrio Therapeutics which is developing a novel antibody platform able to rapidly identify TCR-like antibodies. Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Peter co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ IPOs, fundraisings, and M&A. His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. In addition to serving as a Director of Race Oncology, he is also currently a Director of Myrio Therapeutics, MycRx Inc., Hula Therapeutics Inc. and Amala Therapeutics.

Job Titles:

• Member of the Management Team

Job Titles:

• Chief Financial Officer
• Member of the Management Team
• Director of Prime Accounting & Business Advisory Pty Ltd

Mr Brendan Brown is a Partner and Director of Prime Accounting & Business Advisory Pty Ltd, part of the Prime Financial Group. He is a Chartered Accountant and Registered Tax Agent, and has worked with numerous life science companies over the last 20 years. Mr Brown holds a Bachelor of Commerce (Accounting) from La Trobe University.

Job Titles:

• CEO
• Member of the Board of Directors
• Non - Executive Director

Phil Lynch has over 30 years experience working in Asia Pacific (AP) markets with Johnson & Johnson. He is an experienced Board Director with a diverse background across corporate development, strategy, financial performance, marketing and governance. In his last role he was the Vice President, Commercial Growth where he partnered with the M&A team on integration and growth of acquired businesses in AP. He was previously Managing Director for the the Australian Consumer Health Products Company and in earlier roles led businesses in Thailand, Vietnam and Singapore and Sales & Marketing functions across AP. He's a Business graduate from Monash University, has completed post graduate studies at the University of Virginia Darden Business school and is a Graduate of the Australian Institute of Company Directors.

Job Titles:

• Member of the Board of Directors
• Fellow of the Institute of Managers
• Non - Executive Chair
• Specialist

Mary is a cross sectoral specialist with two decades of board and C-suite Executive experience and a breadth of expertise across all aspects of business management in the biotechnology, pharmaceutical, health and agricultural spheres. She is currently Executive Director (acting) of the Global Health Alliance; Chair of unlisted oncology company, CTxONE and Executive Director of Mary Harney Advisory. Recently, Mary was the Interim CEO of the $2b Breakthrough Victoria fund. In her prior roles as CEO of Royal Australasian College of Surgeons, and Gardiner Dairy Research Foundation; the Director of the Office of Clinical Research/COO Research at Peter MacCallum Cancer Centre and Director of Corporate Development at Bioproperties Pty Ltd, she had carriage of strategy development, risk management and the development of best practice corporate, research and clinical governance. Mary held the Company Secretary role on three occasions since 2000 at Cerylid Biosciences Ltd, the Gardiner Dairy Research Foundation and the Royal Australasian College of Surgeons. She was on the board of the RACS Foundation for Surgery and board committees (Audit and Risk Committees, Governance and People Development) for RACS and Gardiner Foundation. Mary has undergraduate degrees in science and art history from Monash University and University of Melbourne respectively and international postgraduate qualifications in diagnostic Cytopathology. In 2015, she was the collaborative winner, with Monash of the AFR and B-HERT for excellence in collaboration between industry and academia for the dairy industry. In 2016, she was awarded the Science Alumni of the Year award from Monash University. Mary is a Fellow of the Institute of Managers, Member of the Australian Institute of Company Directors (AICD) and completed the AICD course in 2000. In 2017, she completed ‘Strategy in the Age of Digital Disruption' at INSEAD Business School (Global #1 Business School)

Job Titles:

• Member of the Management Team
• Principal Scientist
• Researcher

Professor Michael Kelso is an internationally experienced researcher, with more than 25 years of R&D experience across a wide range of areas in medicinal chemistry, including oncology, antimicrobial drug development and drug formulation. Prior to joining Race Oncology, he was a Professor of Medicinal Chemistry at the University of Wollongong and earlier in his career a NH&MRC CJ Martin Postdoctoral Research Fellow at the Department of Chemistry, The Scripps Research Institute, CA, USA. Prof Kelso has published 69 scientific research papers and 7 patents and has attracted 18 grants from the National Health and Medical Research Council (NH&MRC), Australian Research Council (ARC), and the US National Institutes of Health (NIH), as well as industry and charity foundations. Prof Kelso holds a Bachelor of Medicinal Chemistry (First Class Honours) from the University of Wollongong and a PhD from University of Queensland. He is a member of the Royal Australian Chemical Institute and the American Chemical Society.